A state-of-the-art hyaluronic acid filling-line
The demand for Croma-Pharma's hyaluronic acid fillers led to the construction of a new, state-of-the-art and fully automated manufacturing site which was opened in 2018.
Innovative crosslinking technology
Croma uses an innovative crosslinking technology ("macro") developed in-house to achieve a particularly stable HA matrix. In this process, a special manufacturing step first carefully aligns the hyaluronic acid (HA) chains with each other. The HA gel is then cross-linked using BDDE (a cross-linking agent) to form a three-dimensional matrix. Hyaluronic acid chains are linked together in the process, achieving higher viscosity, cohesiveness and stability.
Stability and safety thanks to automation
Croma relies on tailor-made production lines, which are characterised by their high level of automation. This minimises human influence while guaranteeing a reproducible process, consistently high quality, stability and, as a result, product safety. All production data are recorded and can be analysed in detail. During filling with the restricted area barrier system (RABS), a technology for aseptic filling is used in addition to terminal sterilisation to minimize the risk of contamination through particles and microbes.
- 5,000 Syringes per hour
- 2,200 m² Manufacturing site
- 1,000 m² Clean room